What researchers published on Mantle cell lymphoma
287 papers, newest first.
Showing 80 of 287
Case reportCase Report: Cytomegalovirus retinitis in an HIV-negative patient with splenic mantle cell lymphoma treated with bendamustine-rituximab.Frontiers in immunology
Clinical, histopathological and molecular characterization of mantle cell lymphoma with MALToma-like presentation.Histopathology
Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL.American journal of hematology
The Histone Lactylation of KREMEN2 Inhibits Ferroptosis Through the JAK2/STAT3/GPX4 Axis and Promotes the Progression of Mantle Cell Lymphoma.Hematological oncology
Case report[Composite follicular lymphoma and mantle cell lymphoma: report of a case].Zhonghua bing li xue za zhi = Chinese journal of pathology
Case reportIncidental CD5 Negative Mantle Cell Lymphoma in a Gastrointestinal Stromal Tumor: An Unusual Case Suspicious for a Non-Nodal Variant.International journal of laboratory hematology
Socioeconomic deprivation does not affect survival outcomes in patients with mantle cell lymphoma: evidence from a German nationwide study.Blood cancer journal
Lower baseline eosinophil counts are associated with inferior survival in Mantle cell lymphoma.Leukemia & lymphoma
Treatment patterns and healthcare utilization for patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the Veterans Health Administration (MCLOVA) who were prescribed their first Bruton Tyrosine Kinase inhibitor (BTKi): A national retrospective cohort study.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Racial and socioeconomic differences in time to treatment initiation and outcomes in aggressive non-Hodgkin lymphoma.Blood neoplasia
Real-World Treatment Patterns, Burden of Illness, and Survival of Autologous Stem Cell Transplant-Ineligible Patients With Mantle Cell Lymphoma in Ontario, Canada.EJHaem
Spurious CD34 expression in mantle cell lymphoma due to non-specific binding to PerCP-Cy5.5: A diagnostic pitfall.Cytometry. Part B, Clinical cytometry
Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras.Blood cancer journal
Case reportProgressive Pancytopenia in the Setting of Severe Pneumonia in a Patient With a History of Mantle Cell Lymphoma: A Case Report.Cureus
CAR T-cell therapy for relapsed and refractory B-cell non-Hodgkin lymphoma: a single-centre 5-year real-world experience study at Ghent University Hospital.Acta clinica Belgica
Early Integration of CAR T-Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors.Hematological oncology
Case reportAcute abdominal presentation of mantle cell lymphoma mimicking acute appendicitis: a case report.Journal of surgical case reports
ROR1 upregulation after CD19-CAR T-cell relapse in mantle cell lymphoma identifies a targetable vulnerability for ROR1-directed bispecific modalities.Leukemia
Case reportCase Report: Ischemic central retinal vein occlusion in a patient with relapsed mantle cell lymphoma as a manifestation of suspected cancer-associated hypercoagulability.Frontiers in medicine
Meta-analysisClinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: A systematic literature review and meta-analysis.Journal of managed care & specialty pharmacy
In plain wordsRead moreRead the paper on PubMedCD70-driven immunosuppression in mantle cell lymphoma identifies a vulnerability to CD70-Directed bispecific antibody modalities.Cancer letters
Survival benefit of chemoradiotherapy in limited-stage mantle cell lymphoma: a National Cancer Database analysis.Blood neoplasia
A prospective, multi-center, phase IV clinical study to assess the safety and clinical outcome of acalabrutinib in Indian adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed/refractory mantle cell lymphoma.Frontiers in oncology
Rituximab maintenance following frontline bendamustine-rituximab in mantle cell lymphoma: a systematic review and meta-analysis.Haematologica
Case reportClassic mantle cell lymphoma with aberrant immunohistochemical expression of Fc receptor-like 4/immunoglobulin superfamily receptor translocation-associated 1.BMJ case reports
A Case of Leukemic Phase of Mantle Cell Lymphoma Diagnosed With Scarring Conjunctivitis and Bilateral Upper Palpebral Conjunctival Tumor.Cornea
Observational studyContemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort.Hematological oncology
Case reportCoinfection of Pneumocystis jirovecii and Aspergillus fumigatus in the lung: A case report.Medicine
GuidelineB-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.Journal of the National Comprehensive Cancer Network : JNCCN
In plain wordsRead moreRead the paper on PubMedCase reportExtensive Neurolymphomatosis as the Sole Site of Relapse in Mantle Cell Lymphoma.Clinical nuclear medicine
Targeting ROR1 with KAN571C disrupts resistance networks in mantle cell lymphoma.Blood neoplasia
Treatment of Mantle Cell Lymphoma in Asia: Updated Consensus from the Asian Lymphoma Study Group.Cancer research and treatment
Acalabrutinib Added To Rituximab, Bendamustine (ABR) in Newly Diagnosed High Risk Mantle Cell Lymphoma: an Early Indian Experience.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
Review[Advances in single cell omics applications in mantle cell lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
[CD20-negative/CD10-positive mantle cell lymphoma (blastic variant): a case report].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Case reportCase Report: Occult mantle cell lymphoma in a synchronous rectal collision tumor with adenocarcinoma: retrospective reclassification and multispecimen molecular profiling.Frontiers in oncology
Meta-analysisComparative Efficacy of BTK Inhibitors in Treatment-Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta-Analysis.Journal of cellular and molecular medicine
In plain wordsRead moreRead the paper on PubMedReviewHigh time for risk-adapted treatment in mantle cell lymphoma.The Lancet. Haematology
FDA grants accelerated approval to BCL-2 inhibitor sonrotoclax for mantle cell lymphoma.Cancer
Trial resultCD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.The Lancet. Haematology
In plain wordsRead moreRead the paper on PubMedReviewBTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.Cancers
Systematic reviewCAR T-cell vs bispecific antibodies in relapsed/refractory mantle cell lymphoma: a systematic review and meta-analysis.Frontiers in oncology
In plain wordsRead moreRead the paper on PubMedCase reportMantle cell lymphoma presenting as bullous pemphigoid: a rare paraneoplastic syndrome.BMJ case reports
PreprintSurveying the Genomic Landscape of Mantle Cell Lymphoma Indicates the Importance of Multimodal Genomic and Transcriptomic Exploration.medRxiv : the preprint server for health sciences
Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.Bone marrow transplantation
Trial resultGlofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.British journal of haematology
In plain wordsRead moreRead the paper on PubMedTreatment Preferences for Relapsed/Refractory Mantle Cell Lymphoma Among Patients and Physicians in China: A Discrete Choice Experiment.The patient
Treatment, Monitoring, and Management of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Evidence From a Multi-Country Needs Assessment.Cancer reports (Hoboken, N.J.)
Trial resultTrials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.BMC cancer
Case reportMoraxella nonliquefaciens Keratitis Due to Ocular Surface Disease in a Patient Treated with Zanubrutinib for Mantle Cell Lymphoma.Eye & contact lens
Case reportFirst Case of Concurrent Cytomegalovirus and Aspergillus tamarii Pulmonary Infections in a Mantle Cell Lymphoma Patient: A Case Report and Literature Review.Infection and drug resistance
Case reportLong-term complete remission following treatment with polatuzumab vedotin, rituximab, and bendamustine in a patient with mantle cell lymphoma relapsing after CAR-T cell therapy: a case report.Therapeutic advances in medical oncology
Bruton tyrosine kinase inhibitors plus chemoimmunotherapy in previously untreated younger mantle cell lymphoma patients: Single-centre clinical outcomes.British journal of haematology
How soon is now for new treatments for mantle cell lymphoma?Blood
ReviewRefining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.Expert review of hematology
Review[Recent advances and future perspectives in the treatment of mantle cell lymphoma].[Rinsho ketsueki] The Japanese journal of clinical hematology
Comparative Cardiovascular Safety and Exploratory Bleeding Outcomes of Ibrutinib, Acalabrutinib, and Zanubrutinib in Mantle Cell Lymphoma: A Propensity Score-Matched Real-World Analysis.Cancer medicine
Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant & Cellular Therapies registry study.Internal medicine journal
Trial resultA distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Nature communications
In plain wordsRead moreRead the paper on PubMedReviewEvolution of mantle cell lymphoma therapy: advancing frontline precision.Trends in cancer
Patient Perspectives on Non-Hodgkin Lymphoma: A Qualitative Study to Guide Selection of Clinical Trial Endpoints.Current oncology (Toronto, Ont.)
ReviewFirst-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma.Current oncology (Toronto, Ont.)
Trial resultMolecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.Blood advances
In plain wordsRead moreRead the paper on PubMedIdentifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models.Biomarker research
Palliative total kidney irradiation for acute kidney injury caused by bilateral renal infiltration of chemotherapy-resistant mantle cell lymphoma: a case report.International cancer conference journal
ReviewMantle Cell Lymphoma in Geriatric Patients: Biologic Risk Stratification, Fitness-Adapted Strategies, and Unmet Needs.European journal of haematology
Trial resultAcalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial).Annals of hematology
In plain wordsRead moreRead the paper on PubMedEfficacy and safety analysis of a novel BTK inhibitor in patients with mantle cell lymphoma harboring TP53 mutations.American journal of cancer research
Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real-World Case Series.EJHaem
Healthcare resource utilization analysis in newly diagnosed mantle cell lymphoma: resource alleviation with adoption of the TRIANGLE ibrutinib regimen without autologous stem cell transplantation.Annals of hematology
Randomised trialFirst-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.Blood
In plain wordsRead moreRead the paper on PubMedClinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.Cancers
Systematic reviewAn unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.Journal of medical economics
In plain wordsRead moreRead the paper on PubMedSonrotoclax (Beqalzi) for mantle cell lymphoma.The Medical letter on drugs and therapeutics
Correction: Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States.Frontiers in public health
Randomised trialRituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
In plain wordsRead moreRead the paper on PubMedCase reportSalvage ultra-low-dose radiotherapy for conjunctival mantle cell lymphoma - a case report and literature review.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
Erratum: Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study.British journal of haematology
Reversible and irreversible BTK inhibition promotes stem-like functional multipotency, persistence, and antitumor efficacy of CD19-directed CAR T cells in mantle cell lymphoma.Leukemia